Methods for increasing exosome productivity and compositions comprising exosomes produced thereby
Patent Information
- Application Number
- CN202380017259.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-08
- Filing Date
- 2023-01-16
- Publication Date
- 2024-11-08
AI Technical Summary
[0033] According to embodiments of the present invention, methods for increasing exosome yield are performed by culturing cells treated with high-pressure oxygen under environmental conditions between relatively harsh conditions and relatively favorable conditions (for example, under favorable conditions in stem cell culture processes) This has the effect of improving production efficiency and output.
Smart Images

Figure CN118922532A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for increasing the productivity of exosomes by high-pressure oxygen treatment and a composition comprising the exosomes produced thereby. Background Art
[0002] Exosomes are small membrane-structured vesicles secreted by various types of cells. It is reported that the diameter of exosomes is about 30 to 300nm. Electron microscopy studies have observed that exosomes originate from specific compartments in cells called multivesicular bodies (MVBs) and are released and secreted outside the cells, rather than being directly separated from the plasma membrane. In other words, when the MVBs and plasma membranes fuse, the vesicles are released into the extracellular environment, which are called exosomes. Although the molecular mechanism of the production of these exosomes has not yet been clarified, it is known that not only red blood cells, but also various types of immune cells including B lymphocytes, T lymphocytes, dendritic cells, platelets, macrophages, tumor cells, stem cells, etc., produce and secrete exosomes when they survive.
[0003] In addition, according to the latest research reports, exosomes play an important role in processes such as intercellular signaling and disposal management (Edwin van der pol et al., Pharmacological Reviews July 2012, 64(3)676-705). Exosomes have the potential to be used as biomarkers for disease prognosis, treatment, health and disease, and their clinical applications have recently attracted increasing attention.
[0004] In order to facilitate understanding of the present invention, the background technology of the present invention is described. The contents described in the background technology of the present invention should not be understood as existing prior art. Summary of the invention Technical issues
[0005] At the same time, since the number of exosomes produced by cells is small, a method that can improve the exosome productivity is needed to efficiently obtain a large number of exosomes.
[0006] Therefore, the inventors intended to develop a method that can effectively increase the productivity of exosomes.
[0007] Therefore, the inventors developed a method for increasing the productivity of exosomes by high-pressure oxygen treatment when culturing stem cells.
[0008] The object of the present invention is to provide a method for increasing the productivity of exosomes by high-pressure oxygen treatment during the culture of stem cells.
[0009] The objects of the present invention are not limited to the above objects, and other objects not mentioned will be obvious to those skilled in the art from the following description. Technical Solution
[0010] One aspect of the present invention provides a method comprising culturing a sample containing cells under a first pressure environment; and culturing the sample under a second pressure environment higher than the first pressure, wherein the second pressure condition is generated by high-pressure oxygen.
[0011] In the present invention, "cells" may be all types of somatic cells obtained from the human body, for example, may be at least one selected from the group consisting of: skin, hair follicles, tooth roots, fat, blood, urine, mucus, saliva, tears, plasma, serum, urine, sputum, cerebrospinal fluid, pleural effusion, nipple aspirate, lymphatic fluid, respiratory fluid, intestinal fluid, urogenital fluid, breast milk, lymphatic fluid, semen, cerebrospinal fluid, tracheal fluid, ascites, cystic tumor fluid, amniotic fluid, and combinations thereof. In addition, "cells" may be cells obtained from organisms other than humans, such as plants or animals, in addition to somatic cells obtained from the human body.
[0012] In the present invention, "exosomes" refer to small membrane vesicles with a lipid bilayer derived from endosomes released by cells. Exosomes may refer to small vesicles that contain proteins, DNA, RNA, etc. and are secreted outside the cells to transmit signals between cells. They may include proteins, lipids, mRNA, microRNA (miRNA) and genomic DNA, etc.
[0013] In an exemplary embodiment, the stem cell-derived exosomes may include a marker protein selected from the group consisting of CD9, CD63, CD81, and a combination thereof, but are not limited thereto.
[0014] Specifically, since CD9, CD63, and CD81 are representative positive markers of exosomes, the contents of CD9, CD63, and CD81 have a linear relationship with the content of exosomes, and an increase in the content of CD9, CD63, and CD81 means that the content of exosomes increases proportionally.
[0015] In a specific exemplary embodiment, exosomes are not limited, but can be obtained, extracted or separated from fat or human blood. In addition, exosomes can also be extracted from stem cells or immune cells. Stem cells can be embryonic stem cells, induced pluripotent stem cells (iPSC), adult stem cells, mesenchymal stem cells derived from embryonic stem cells, or mesenchymal stem cells derived from induced pluripotent stem cells. Immune cells can be T cells, B cells, NK cells, cytotoxic T cells, dendritic cells or macrophages. In addition, exosomes can be obtained, extracted or separated from cells of organisms such as plants or animals other than humans.
[0016] In addition, as an embodiment that does not limit the present invention, the adult stem cell can be one or more adult stem cells selected from the group consisting of mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells and pluripotent stem cells. Mesenchymal stem cells can be mesenchymal stem cells obtained from one or more tissues selected from the group consisting of umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, amniotic membrane, Wharton's jelly and placenta. Preferably, the adult stem cell can be a mesenchymal stem cell, for example, a stem cell obtained from fat, bone marrow, umbilical cord or umbilical cord blood, more preferably, a stem cell obtained from fat.
[0017] In a specific exemplary embodiment, when exosomes are extracted from stem cells, the stem cells can be stem cells (such as human adipose tissue) isolated from adipose tissue (such as human adipose tissue), but are not limited thereto, and can include all cells that can differentiate into one or more mesenchymal cells, such as fat, bone, cartilage and muscle fibers. Adipose-derived stem cells (ADSCs) can be at least one of preadipocytes, stromal cells, multipotent adipose-derived cells or adipose-derived adult stem cells.
[0018] The type of stem cells or immune cells is not limited as long as there is no risk of pathogen infection and no immune rejection reaction is induced, but human stem cells or human immune cells are preferred.
[0019] However, it should be understood that the cells may include various animal cells and plant cells that have been used or may be used in the art in the future. The adipose stem cells used in the embodiments to be described below are an example of animal cells that can be used in the present invention, but are not limited to this.
[0020] In the present invention, the "sample" may be at least one selected from the group consisting of: blood, urine, mucus, saliva, tears, plasma, serum, urine, sputum, cerebrospinal fluid, pleural effusion, nipple aspirate, lymph fluid, respiratory fluid, intestinal fluid, urogenital fluid, breast milk, lymphatic fluid, semen, cerebrospinal fluid, tracheal fluid, ascites, cystic tumor fluid, amniotic fluid, and combinations thereof, all of which are obtained from the human body, and may include cell culture medium, but is not limited thereto, as long as the sample is any sample that secretes exosomes. Here, the culture medium may include fetal bovine serum (FBS), but is not limited thereto, and the commercially available CellCor® of Xcell Therapeutics may be used. TM CD MSC, STEMCELLtechnology’s MesenCult TM plus, Peprotech's eproGrow TMhMSC (mesenchymal stem cell) culture medium, BI / Satorius MSC series, StemMACS by Miltenyi biotec TM , RoosterNourish by Roosterbio TM 、StemXVivo by R&D systems TM 、Takara Bio MSC XF, PRIME-XV XSFM or PRIME-XV SFM from IrvineScience / FUJI, StemFit for MSC from Aiinomoto, TheraPEAK from Lonza TM , Cellntec’s CnT-PR-MSC-XF, etc.
[0021] For example, blood is a body fluid that provides oxygen and nutrients to cells in the body and recycles and carries carbon dioxide and waste products produced by cell metabolism. Plasma is the liquid component of blood and is a solvent that dissolves various organic and inorganic substances (including proteins). Serum or body fluid is a component of blood and refers to the yellow liquid component remaining after fibrinogen is removed from plasma.
[0022] For example, blood refers to a body fluid that provides oxygen and nutrients to body cells and recovers and carries carbon dioxide and waste products produced by cell metabolism. Plasma is the liquid component that makes up blood and is a solvent that dissolves various organic and inorganic substances (including proteins). Serum or fluid is a component of blood and refers to the yellow liquid component remaining after fibrinogen is removed from plasma.
[0023] A method for improving the productivity of exosomes according to a specific exemplary embodiment of the present invention is characterized in that it is possible to achieve improved production efficiency and yield. More specifically, during the stem cell culture process, environmental conditions between general culture conditions and favorable conditions are changed, such as pressure conditions, oxygen concentration conditions, carbon dioxide concentration conditions, nitrogen concentration conditions, air composition conditions, light source wavelength conditions and temperature conditions in the incubator, and high-pressure oxygen is processed, thereby improving the production efficiency and yield of exosomes.
[0024] In a specific exemplary embodiment, the method includes culturing a sample containing cells under a first pressure environment; culturing the sample under a second pressure environment higher than the first pressure, wherein the second pressure condition is generated by high-pressure oxygen to increase the production efficiency and yield of exosomes, but is not limited thereto.
[0025] More specifically, the method may further include extracting exosomes from the sample, but is not limited thereto.
[0026] More specifically, the cell may be a stem cell, but is not limited thereto.
[0027] More specifically, the culturing under the first pressure environment and the culturing under the second pressure environment may be repeated two or more times, but is not limited thereto.
[0028] More specifically, the second pressure may be 1 to 5 ATA, but is not limited thereto.
[0029] More specifically, the sample incubation time under the second pressure environment may be 60 to 120 minutes, but is not limited thereto.
[0030] In the present disclosure, the terms "yield" and "yield" refer to the number of exosomes obtainable from a predetermined sample, and refer to measurements performed by general quantitative methods (including the experimental methods described in the Examples).
[0031] In a specific exemplary embodiment, in the method for improving the production efficiency and yield of exosomes, the production efficiency and yield can be defined as the number of exosome particles per mL of exosome culture fluid.
[0032] The present invention will be described in more detail below by way of examples. However, these examples are only used to illustrate the present invention, and the scope of the present invention is not limited to these examples. Beneficial Effects
[0033] According to an embodiment of the present invention, the method for improving the yield of exosomes has the effect of improving production efficiency and yield by culturing cells treated with high-pressure oxygen under environmental conditions between relatively harsh conditions and relatively favorable conditions (such as favorable conditions in stem cell culture).
[0034] More specifically, the high pressure oxygen as a favorable condition can be treated 1 to 5 times at 1 to 5 ATA, each time for 60 to 120 minutes, preferably, 3 times at 3 ATA, each time for 90 minutes. Thus, the production efficiency and yield of exosomes are improved.
[0035] The effects according to the present invention are not limited to the contents of the above-mentioned examples, and further various effects are also included in this specification. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 is a schematic diagram illustrating a high temperature oxygen treatment method according to an embodiment of the present invention.
[0037] Figure 2 is a schematic diagram illustrating the size and concentration distribution of exosomes in the control group A0 according to the nanoparticle tracking analysis (NTA) results.
[0038] Figure 3is a schematic diagram illustrating the size and concentration distribution of exosomes in experimental group A1 according to the nanoparticle tracking analysis (NTA) results.
[0039] Figure 4 is a schematic diagram illustrating the size and concentration distribution of exosomes in experimental group A2 according to the nanoparticle tracking analysis (NTA) results.
[0040] Figure 5 is a schematic diagram illustrating the size and concentration distribution of exosomes in experimental group A3 according to the nanoparticle tracking analysis (NTA) results. DETAILED DESCRIPTION
[0041] Although the embodiments of the present invention have been described in detail with reference to the accompanying drawings, the present invention is not limited thereto and can be embodied in many different forms without departing from the technical concept of the present invention.
[0042] Therefore, the embodiments of the present invention are only for illustrative purposes and are not intended to limit the technical concepts of the present invention. The scope of the technical concepts of the present invention is not limited thereto. Therefore, it should be understood that the above embodiments are illustrative in all aspects and are not limited thereto. The protection scope of the present invention should be interpreted based on the attached claims, and all technical ideas within the equivalent scope should be interpreted as belonging to the scope of the present invention.
[0043] The present invention will be described in more detail below by way of examples. However, these examples are intended to illustrate one or more exemplary embodiments, and the scope of the present invention is not limited to these examples. Example 1. Cell culture
[0044] To extract exosomes, 70cc of fat was extracted from the lower abdomen of healthy adult men aged 30 to 40 years, and the stromal vascular fraction (SVF) was extracted and then frozen at normal pressure in a nitrogen tank at -196°C.
[0045] Afterwards, the frozen SVF was thawed and inoculated into a culture flask, and cultured in a 37°C, air, and 5% CO2 incubator for 7 days using DMEM (Dulbecco's Modified Eagle Medium) medium containing fetal bovine serum (FBS), 100 units / mL penicillin, and 100 μg / mL streptomycin, and further cultured for 18 days under the same conditions to obtain sufficient stem cells. Example 2. High-pressure oxygen treatment
[0046] The cells cultured in Example 1 were divided into four groups, namely A0, A1, A2 and A3, and treated with high-pressure oxygen for the following number of times.
[0047] Each sample was dispensed into 105 cells (10 ml), two wells were added to each of the control group and the experimental group, and then the experiment was carried out.
[0048] When treated with high-pressure oxygen, the cells were cultured in a high-pressure oxygen box at 3ATA for 90 minutes. When not treated with high-pressure oxygen, the cells were cultured in a common incubator at 37°C, air and 5% CO2.
[0049] More specifically, if Figure 1 As shown, the control group A0 was not treated with high-pressure oxygen and cultured in a normal incubator for 4 days. The experimental group A1 was cultured in a high-pressure oxygen box once on the first day of culture, and then cultured in a normal incubator for 70.5 hours; the experimental group A2 was cultured in a high-pressure oxygen box twice, once on the first and second days of culture, and then cultured in a normal incubator for 46.5 hours; the experimental group A3 was cultured in a high-pressure oxygen box three times, once on the first, second and third days of culture, and then continued to culture in a normal incubator for 22.5 hours. Thereafter, on the fourth day of culture, all the control group A0 and experimental groups A1 to A3 were collected, and the culture fluid of a total of 8 wells was frozen in a -196℃ nitrogen tank. Example 3. Exosome extraction and characterization analysis
[0050] In order to measure the yield and production of exosomes from the cells cultured in Example 1 and the stem cells treated with high temperature oxygen in Example 2, culture fluids were obtained from the control group and the experimental group, respectively, and then exosomes were separated using an aqueous two-phase system (ATPS) method.
[0051] Nanoparticle tracking analysis was performed on the isolated exosomes to measure particle size and concentration.
[0052] Results, such as Figures 2 to 5 As shown in Table 1, it was confirmed that the separated exosomes were distributed in a size range of about 200 nm (the conventional size range of exosomes), and the particle size distribution was substantially uniform, satisfying the size and distribution characteristics of exosomes. In addition, as shown in Table 1, it was demonstrated that in the treatments A1 to A3 with high-pressure oxygen, the number concentration of exosomes increased as the number of high-pressure oxygen treatments increased, thereby improving the productivity of exosomes. [Table 1]
[0053] In addition, the isolated exosomes were subjected to flow cytometry to confirm the presence of CD9, CD63, and CD81 markers.
[0054] Since CD9, CD63, and CD81 are representative exosome positive markers, the contents of CD9, CD63, and CD81 have a linear relationship with the content of exosomes, and an increase in the content of CD9, CD63, and CD81 means that the content of exosomes increases proportionally.
[0055] Specifically, in order to isolate CD81-positive exosomes, the Exosome-Human CD81 Isolation / Detection Kit (Thermo Fisher Scientific) was used according to the manufacturer's instructions, and the markers were stained using PE-mouse anti-human CD9 antibody (PE-mouse anti-human CD9; BD Biosciences), PE-mouse anti-human CD63 antibody (PE-mouse anti-human CD63; BD Biosciences) and PE-mouse anti-human CD81 antibody (PE-mouse anti-human CD81; BD Biosciences), and then analyzed using a flow cytometer (ACEA Biosciences). As shown in Figure 6, the exosomes isolated in Example 2 were positive for positive markers CD9, CD63 and CD81. These results show that the isolated exosomes meet the specific marker characteristics that must exist in exosomes.
[0056] Therefore, it was confirmed that the present invention can efficiently obtain and mass-produce exosomes at a high yield.
[0057] Meanwhile, the above experiments were conducted in a common incubator and an incubator capable of high-pressure oxygen treatment, but are not limited thereto, and the method according to the present invention can be conducted in a bioreactor capable of internally controlling pressure. That is, the method of the present invention can be performed by alternately culturing samples between incubators having two pressure conditions, or the method of the present invention can also be performed by changing the pressure conditions of the space within the bioreactor.
[0058] Although the embodiments of the present invention have been described in detail with reference to the accompanying drawings, the present invention is not limited thereto, and the present invention can be embodied in a variety of different forms without departing from the technical concept of the present invention. Therefore, the embodiments disclosed in the present invention are not intended to limit the technical spirit of the present invention, but to describe the present invention, and the scope of the technical spirit of the present invention is not limited by these embodiments. Therefore, it should be understood that the above-mentioned embodiments are illustrative in all aspects and do not limit the present invention. The scope of protection of the present invention should be interpreted on the basis of the attached claims, and all technical ideas within the equivalent scope should be interpreted as belonging to the scope of the present invention.
Claims
1. A method for improving exosome productivity, comprising: culturing a sample comprising cells under a first pressure environment; as well as Incubate the sample under a second pressure environment higher than the first pressure, The second pressure condition is generated by high pressure oxygen.
2. The method for improving exosome productivity according to claim 1, further comprising: Exosomes are extracted from the sample.
3. The method for increasing exosome productivity according to claim 1, wherein the cells are stem cells. 4 . The method for improving exosome productivity according to claim 1 , wherein the culturing under the first pressure environment and the culturing under the second pressure environment are repeated two or more times. 5 . The method for improving exosome productivity according to claim 1 , wherein the second pressure is 1 to 5 ATA. 6 . The method for improving exosome productivity according to claim 1 , wherein the sample is cultured under the second pressure environment for 60 to 120 minutes.
7. A method containing 5x10 9 A composition of exosomes having a concentration of or more.
